Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals has allotted 46,43,000 convertible equity warrants to promoter group entities and individuals at Rs. 34 per warrant, aggregating to about Rs. 15.79 crore on a preferential basis. The company has already received 25% of the consideration (Rs. 3.95 crore), with the remaining 75% (Rs. 11.84 crore) to be paid upon exercise of the warrants within 18 months. Each warrant is convertible into one equity share of Re. 1 face value. Post conversion, promoter holding will marginally increase from 49.73% to 50.26% on a diluted basis. The issue price was determined as per SEBI ICDR Regulations.
This is a promoter-backed capital infusion that strengthens the company's equity base without immediately diluting shareholders, since paid-up capital remains unchanged until warrants are exercised. Retail investors may view this as a sign of promoter confidence, though future share count will rise if warrants are converted within 18 months.